Form 4: Clover Health CEO Sells Shares Under Pre-Arranged Trading Plan

Jamie L. Reynoso, CEO of Medicare Advantage at Clover Health Investments, Corp., sold a total of 21,801 Class A Common Stock shares and had 8,706 shares withheld for tax obligations in early July 2025, all under a Rule 10b5-1 trading plan.

Summary

• Jamie L. Reynoso, CEO of Medicare Advantage at Clover Health Investments, Corp. (CLOV), reported multiple transactions involving Class A Common Stock.
• On July 3, 2025, Reynoso sold 19,789 shares of Class A Common Stock at a weighted average price of $2.58 per share, with prices ranging from $2.54 to $2.63.
• Also on July 3, 2025, 8,706 shares of Class A Common Stock were automatically withheld at a price of $2.56 to cover tax obligations related to the vesting of restricted stock units (RSUs).
• On July 7, 2025, Reynoso sold an additional 2,012 shares of Class A Common Stock at a weighted average price of $2.85 per share, with prices ranging from $2.81 to $2.88.
• Both sales transactions were executed pursuant to a Rule 10b5-1 trading plan adopted by Reynoso on March 13, 2025.
• The RSU vesting on July 3, 2025, represented 6.25% of the RSUs granted on January 3, 2023.
• Following these transactions, Jamie L. Reynoso beneficially owns 3,297,821 shares of Class A Common Stock directly.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While insider sales can be perceived negatively, the fact that they were conducted under a pre-arranged 10b5-1 plan mitigates concerns about opportunistic selling. The RSU vesting also indicates continued executive compensation and retention.

Positives

• The vesting of restricted stock units indicates continued compensation and retention of a key executive, Jamie L. Reynoso, through equity incentives.
• The sales were conducted under a Rule 10b5-1 trading plan, which suggests the transactions were pre-scheduled and not based on immediate, non-public information, potentially mitigating negative perceptions of insider selling.

Negatives

• The sale of 21,801 shares by a high-ranking executive reduces their direct ownership stake in the company, which could be perceived by some investors as a lack of confidence, despite the pre-planned nature of the sales.

Risks

• Insider selling, even when pre-planned, can sometimes be interpreted negatively by the market and potentially contribute to downward pressure on the stock price.

Future Outlook

Remaining restricted stock units granted to Jamie L. Reynoso on January 3, 2023, will continue to vest in equal quarterly installments, with the final vesting occurring on January 3, 2027, subject to continued service.

Related Party Transactions

• Jamie L. Reynoso, an executive officer (CEO, Medicare Advantage) of Clover Health Investments, Corp., engaged in sales of Class A Common Stock and had shares withheld for tax obligations related to RSU vesting. These are transactions between an insider and the company's securities.

Stakeholder Impact

• Shareholders: The sale of shares by a key executive could influence investor sentiment and potentially the stock price, although the pre-planned nature of the sales under a 10b5-1 plan may reduce the perceived negative signal.
• Employees: The vesting of RSUs and continued service of the CEO of Medicare Advantage indicates stability in executive compensation and leadership within a key segment of the company.

Next Steps

• Continued quarterly vesting of Jamie L. Reynoso's remaining restricted stock units until January 3, 2027.

Key Dates

Keywords

Clover Health, CLOV, Form 4, insider trading, stock sale, restricted stock units, RSU vesting, Rule 10b5-1 plan, executive compensation, Jamie L. Reynoso